Observation for Efficacy of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy

Efficacy Observation of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000607

Enrollment

Unknown

Registered

2009-11-28

Start date

2008-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

A:Methylprednisolone 0.4mg/kg * 8 weeks, reduction to 5mg / d to maintain, MMF 0.75 bid * 6 months after the reduction (weight <50kg, MMF0.5 bid)

B:ethylprednisolone 0.4mg/kg*8 weeks, reduction to 5mg / d to maintain

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Renal biopsy proven IgA nephropathy; 2. Proteinuria levels >=1.0g/24hr; 3. Age range 18-70 years, male and female; 4. Scr=30ml/min; 5. Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hypertension, diabetes, obesity, hepatic disease, infection or malignancies; 2. Pregnant or lactating women; 3. Receive continuous treatment of steroid and other immunosuppressive drug for more than 3 months within one year before the study; 4. Secondary IgA nephropathy; 5. Renal biopsy proven lupus nephritis V or severe renal interstitial injury.

Design outcomes

Primary

Measure	Time frame
Renal function;24-hour urine protein;	—

Secondary

Measure	Time frame
Urea routine test;Serum albumin;eGFR;Blood lipids;Serum globulin;Blood routine test;	—

Countries

China

Contacts

Public ContactXiaoqiang Ding

dxq93216@medmail.com.cn+86 021 64041990-2138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026